NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS NASDAQ) stock market data APIs
$35.8351
0.85(2.4%)
as of October 24, 2025
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Data Overview
Price chart is built with
Anychart
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
35.8351
Open
36.685
High
37.1681
Low
34.7901
52 wk Range
14.06-41.47
Market Cap
4 023 M
Shares Outstanding
113 M
Revenue
64 006 K
EPS
-0.15
Beta
0.027
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with NewAmsterdam Pharma Company N.V. Ordinary Shares (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Ordinary Shares data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental Data
NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental data includes:
- Net Revenue: 64 006 K
- EBITDA: -172 616 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.44
Get NewAmsterdam Pharma Company N.V. Ordinary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares News
New
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Entera Bio First-time presentation examining bone outcomes in early postmenopausal women JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of o...
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
NewAmsterdam REMBRANDT clinical trial to leverage Caristo CaRi-Heart® and CaRi-PlaqueTM technologies for coronary inflammation and plaque measurements and monitoring STAMFORD, Conn. and OXFORD, Eng...
8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments
Why NewAmsterdam Pharma (NAMS) Is Up 7.5% After Late-Stage Obicetrapib Trial Optimism
NewAmsterdam Pharma Company N.V. recently saw a spike in trader interest following optimism around its investigational drug candidate, obicetrapib, which is undergoing three pivotal late-stage trials ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
